Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1)
Citation
Belinda R Lennox, Giuliano Tomei,Sally-Anne Vincent, Ksenija Yeeles,Rebecca Pollard, Emma Palmer-Cooper,Peter Jones, Michael S Zandi, Alasdair Coles. Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1) J Neurol Neurosurg Psychiatry June 2018
Abstract
The main finding of the SINAPPS1 study is that immunotherapy can be delivered rapidly and safely to people with acute psychosis within an acute hospital setting. The treatments were tolerated and there were no cases of worsening of psychotic symptoms, even with the use of corticosteroids. At 1 month after presentation, all patients had improved, although an uncontrolled study of this size cannot determine causality; that is the aim of the on-going randomised placebo-controlled SINAPPS2 trial, whose design was influenced by the current trial.
Description
Copyright information: © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Eligible users can access the full text via NHS OpenAthens (login required).